mTORC1 accelerates osteosarcoma progression via m 6 A-dependent stabilization of USP7 mRNA

Zhengming Yang,Wei Yu,Ankai Xu,Bing Liu,Libin Jin,Huimin Tao,Dimin Wang

DOI: https://doi.org/10.1038/s41420-024-01893-9

2024-03-12

Cell Death Discovery

Abstract:Osteosarcoma (OS) is considered a sex steroid hormone-dependent bone tumor. The development and progression of OS are regulated by 17β-estradiol (E2). However, the detailed mechanisms of E2-modulated OS progression remained to be elucidated. Here, we found that E2-activated mammalian target of rapamycin (mTOR) signaling promoted N6-methyladenosine (m 6 A) modification through regulating WTAP. Inhibition of mTOR complex 1 (mTORC1) reversed E2-activated WTAP expression. Meanwhile, inhibition of mTORC1 suppressed OS cell proliferation and migration. Deficiency of TSC2 activated mTORC1 signaling and enhanced OS cell proliferation and migration, while abrogated by Rapamycin. Interestingly, mTOMC1 promoted mRNA stability of ubiquitin-specific protease 7 (USP7) through m 6 A modification. Loss of USP7 suppressed the proliferation, migration, and ASC specks, while promoted apoptosis of OS cells. USP7 interacted with NLRP3 and deubiquitinated NLRP3 through K48-ubiquitination. USP7 was upregulated and positive correlation with NLRP3 in OS patients with high level of E2. Loss of USP7 suppressed the progression of OS via inhibiting NLRP3 inflammasome signaling pathway. Our results demonstrated that E2-activtated mTORC1 promoted USP7 stability, which promoted OS cell proliferation and migration via upregulating NLRP3 expression and enhancing NLRP3 inflammasome signaling pathway. These results discover a novel mechanism of E2 regulating OS progression and provide a promising therapeutic target for OS progression.

cell biology

What problem does this paper attempt to address?

The problem that this paper attempts to solve is to explore how 17β - estradiol (E2) promotes N6 - methyladenosine (m6A) modification by activating the mTORC1 signaling pathway, thereby stabilizing the mRNA of ubiquitin - specific protease 7 (USP7) and further affecting the progression of osteosarcoma (OS). Specifically, the study focused on the following points:

1. **The influence of E2 on the mTORC1 signaling pathway**:
- The study found that E2 can activate the mTORC1 signaling pathway, thereby up - regulating the expression of WTAP and enhancing m6A modification.
- Inhibiting mTORC1 can reverse the WTAP expression activated by E2 and inhibit the proliferation and migration of OS cells.

2. **The influence of m6A modification on the stability of USP7 mRNA**:
- mTORC1 enhances the stability of USP7 mRNA through m6A modification.
- The deletion of WTAP will significantly reduce the stability of USP7 mRNA, thereby reducing the expression of USP7.

3. **The function of USP7 in OS cells**:
- USP7 increases the expression of NLRP3 and the formation of ASC specks by deubiquitinating NLRP3 (especially K48 - linked ubiquitination).
- The deletion of USP7 will inhibit the proliferation and migration of OS cells and promote apoptosis at the same time.

4. **The role of NLRP3 inflammasome in the progression of OS**:
- The activation of NLRP3 inflammasome is closely related to the progression of OS.
- USP7 promotes the activation of NLRP3 inflammasome by stabilizing NLRP3, thereby accelerating the progression of OS.

In summary, this paper aims to reveal that E2 promotes the progression of osteosarcoma by activating the mTORC1 signaling pathway, enhancing m6A modification, stabilizing USP7 mRNA, and then activating the NLRP3 inflammasome. This mechanism provides a new potential target for the treatment of osteosarcoma.